{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:02:01Z","timestamp":1768485721088,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Dosing recommendations for the treatment of pregnancy-acquired toxoplasmosis are empirical and widely based on experimental data. There are no pharmacological data on pregnant women with acute <jats:italic>Toxoplasma gondii<\/jats:italic> infection under treatment with pyrimethamine (PY) and sulfadiazine (SA) and our study intends to tighten this gap.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In this retrospective case\u2013control study, we included 89 pregnant women with primary <jats:italic>Toxoplasma<\/jats:italic> infection (PT) treated with PY (50\u00a0mg first dose, then 25\u00a0mg\/day), SA (50\u00a0mg\/kg of body weight\/day), and folinic acid (10\u201315\u00a0mg per week). These were compared to a group of 17 women with acute ocular toxoplasmosis (OT) treated with an initial PY dose of 75\u00a0mg, thereafter 25\u00a0mg twice a day but on the same SA and folinic acid regimen. The exact interval between drug intake and blood sampling and co-medication had not been recorded. Plasma levels of PY and SA were determined 14\u2009\u00b1\u20094\u00a0days after treatment initiation using liquid chromatography\u2013mass spectrometry and compared using the Mann\u2013Whitney <jats:italic>U<\/jats:italic> test at a <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 level.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In 23 PT patients (26%), SA levels were below 20\u00a0mg\/l. Fifteen of these 23 patients (17% of all patients) in parallel presented with PY levels below 700\u00a0\u00b5g\/l. Both drug concentrations differed remarkably between individuals and groups (PY: PT median 810\u00a0\u00b5g\/l, 95% CI for the median [745; 917] vs. OT 1230\u00a0\u00b5g\/l [780; 1890], <jats:italic>p<\/jats:italic>\u2009=\u20090.006; SA: PT 46.2\u00a0mg\/l [39.9; 54.4] vs. OT 70.4\u00a0mg\/l [52.4; 89], <jats:italic>p<\/jats:italic>\u2009=\u20090.015) despite an identical SA dosing scheme.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>SA plasma concentrations were found in the median 34% lower in pregnant women with PT compared to OT patients and fell below a lower reference value of 50\u00a0mg\/l in a substantial portion of PT patients. The interindividual variability of plasma concentrations in combination with systematically lower drug levels and possibly a lower compliance in pregnant women may thus account for a still not yet supportable transmission risk. Systematic drug-level testing in PT under PY\/SA treatment deserves to be considered.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s40001-020-00458-7","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T13:03:39Z","timestamp":1606136619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case\u2013control study"],"prefix":"10.1186","volume":"25","author":[{"given":"Ingrid","family":"Reiter-Owona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Hlobil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Enders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Klarmann-Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Gruetzmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Rilling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-5082","authenticated-orcid":false,"given":"Justus G.","family":"Garweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"458_CR1","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1128\/AAC.36.5.1040","volume":"36","author":"R McLeod","year":"1992","unstructured":"McLeod R, Mack D, Foss R, et al. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother. 1992;36:1040\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"458_CR2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/j.1651-2227.2005.tb01844.x","volume":"94","author":"L Gras","year":"2005","unstructured":"Gras L, Wallon M, Pollak A, et al. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centres. Acta Paediatr. 2005;94:1721\u201331.","journal-title":"Acta Paediatr"},{"key":"458_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/cid\/cis234","volume":"54","author":"A Hotop","year":"2012","unstructured":"Hotop A, Hlobil H, Gro\u00df U. Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2012;54:1545\u201352.","journal-title":"Clin Infect Dis"},{"key":"458_CR4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/cid\/cit032","volume":"56","author":"M Wallon","year":"2013","unstructured":"Wallon M, Peyron F, Cornu C, et al. Congenital Toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis. 2013;56:1223\u201331.","journal-title":"Clin Infect Dis"},{"issue":"386","key":"458_CR5","first-page":"e1","volume":"219","author":"L Mandelbrot","year":"2018","unstructured":"Mandelbrot L, Kieffer F, Sitta R, et al. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol. 2018;219(386):e1-9.","journal-title":"Am J Obstet Gynecol"},{"key":"458_CR6","doi-asserted-by":"publisher","first-page":"e20163860","DOI":"10.1542\/peds.2016-3860","volume":"139","author":"YA Maldonado","year":"2017","unstructured":"Maldonado YA, Read JS. Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. Pediatrics. 2017;139:e20163860.","journal-title":"Pediatrics"},{"key":"458_CR7","first-page":"483","volume":"3","author":"D Eyles","year":"1953","unstructured":"Eyles D, Coleman N. Synergistic effect of sulphadiazine and daraprim against experimental toxoplasmosis in the mouse. Antibiot Chemother. 1953;3:483\u201390.","journal-title":"Antibiot Chemother"},{"key":"458_CR8","first-page":"529","volume":"5","author":"DE Eyles","year":"1955","unstructured":"Eyles DE, Coleman N. An evaluation of the curative effects of pyrimethamine and sulfadiazine, alone and in combination, on experimental mouse toxoplasmosis. Antibiot Chemother. 1955;5:529\u201339.","journal-title":"Antibiot Chemother"},{"key":"458_CR9","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jama.1960.03020310059017","volume":"173","author":"JK Frenkel","year":"1960","unstructured":"Frenkel JK, Weber RW, Lunde MN. Acute toxoplasmosis. Effective treatment with pyrimethamine, sulfadiazine, leucovorin calcium, and yeast. JAMA. 1960;173:1471\u20136.","journal-title":"JAMA"},{"key":"458_CR10","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1128\/AAC.33.10.1753","volume":"33","author":"F Derouin","year":"1988","unstructured":"Derouin F, Chastang C. In vitro effects of folate inhibitors on Toxoplasma gondii. Antimicrob Agents Chemother. 1988;33:1753\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"458_CR11","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1128\/AAC.01203-07","volume":"52","author":"P Meneceur","year":"2008","unstructured":"Meneceur P, Bouldouyre MA, Aubert D, et al. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone. Antimicrob Agents Chemother. 2008;52:1269\u201377.","journal-title":"Antimicrob Agents Chemother"},{"key":"458_CR12","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2307\/3279470","volume":"61","author":"HG Sheffield","year":"1975","unstructured":"Sheffield HG, Melton ML. Effect of pyrimethamine and sulfadiazine on the fine structure and multiplication of Toxoplasma gondii in cell cultures. J Parasitol. 1975;61:704\u201312.","journal-title":"J Parasitol"},{"key":"458_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1128\/AAC.39.1.137","volume":"39","author":"E van de Schoondermark ven","year":"1995","unstructured":"van de Schoondermark ven E, Galama J, Vree T, et al. Study of treatment of congenital Toxoplasma gondii infection in rhesus monkeys with pyrimethamine and sulfadiazine. Antimicrob Agents Chemother. 1995;39:137\u201344.","journal-title":"Antimicrob Agents Chemother"},{"key":"458_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/infdis\/157.3.580","volume":"157","author":"LM Weiss","year":"1988","unstructured":"Weiss LM, Harris C, Berger M, Tannowitz HB, Wittner M. Pyrimethamine concentrations in serum and cerebral fluid during treatment of acute toxoplasma encephalitis in patients with AIDS. J Infect Dis. 1988;157:580\u20133.","journal-title":"J Infect Dis"},{"key":"458_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/BF01743370","volume":"24","author":"H Klinker","year":"1996","unstructured":"Klinker H, Langmann P, Richter E. Pyrimethamine alone as prophylaxis for cerebral toxoplasmosis in patients with advanced HIV infection. Infection. 1996;24:324\u20137.","journal-title":"Infection"},{"key":"458_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1086\/590149","volume":"47","author":"JG Montoya","year":"2008","unstructured":"Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008;47:554\u201366.","journal-title":"Clin Infect Dis"},{"key":"458_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4269\/ajtmh.1992.46.288","volume":"46","author":"LM Weiss","year":"1992","unstructured":"Weiss LM, Luft BJ, Tanowitz HB, Wittner M. Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis. Am J Trop Med Hyg. 1992;46:288\u201391.","journal-title":"Am J Trop Med Hyg"},{"key":"458_CR18","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1128\/AAC.48.10.3794-3800.2004","volume":"48","author":"S Corvaisier","year":"2004","unstructured":"Corvaisier S, Charpiat B, Mounier C, et al. Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. Antimicrob Agents Chemother. 2004;48:3794\u2013800.","journal-title":"Antimicrob Agents Chemother"},{"key":"458_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1365-2125.2004.02077.x","volume":"57","author":"T Trenque","year":"2004","unstructured":"Trenque T, Simon S, Villena I, et al. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. Br J Clin Pharmacol. 2004;57:735\u201341.","journal-title":"Br J Clin Pharmacol"},{"key":"458_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00431-005-1665-4","volume":"165","author":"DR Schmidt","year":"2006","unstructured":"Schmidt DR, Hogh B, Andersen O, Hansen SH, Dalhoff K, Petersen E. Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine. Eur J Pediatr. 2006;165:19\u201325.","journal-title":"Eur J Pediatr"},{"key":"458_CR21","first-page":"87","volume":"57","author":"B Lipka","year":"2011","unstructured":"Lipka B, Milewska-Bobula B, Filipek M. Monitoring of plasma concentration of pyrimethamine (PYR) in infants with congenital Toxoplasma gondii infection\u2014own observations. Wiad Parazytol. 2011;57:87\u201392.","journal-title":"Wiad Parazytol"},{"key":"458_CR22","unstructured":"WHO: Second meeting of the subcommittee of the expert committee on the selection and use of essential medicines, Geneva 29 September to 3 October 2008. https:\/\/www.who.int\/selection_medicines\/committees\/subcommittee\/2\/sulfadiazine_rev.pdf."},{"key":"458_CR23","first-page":"65","volume":"10","author":"P Langmann","year":"2004","unstructured":"Langmann P, Schirmer D, Zilly M, Klincker H. Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART. Med Sci Monit. 2004;10:65\u20139.","journal-title":"Med Sci Monit"},{"key":"458_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fphar.2014.00065","volume":"5","author":"MM Costantine","year":"2014","unstructured":"Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5:65.","journal-title":"Front Pharmacol"},{"key":"458_CR25","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1093\/cid\/ciu724","volume":"60","author":"AR Prusa","year":"2015","unstructured":"Prusa AR, Kasper DC, Pollak A, Gleiss A, Waldhoer T, Hayde M. The Austrian Toxoplasmosis Register, 1992\u20132008. Clin Infect Dis. 2015;60:e4-10.","journal-title":"Clin Infect Dis"},{"key":"458_CR26","doi-asserted-by":"publisher","unstructured":"Newton E. Global library of women's medicine. (ISSN: 1756\u20132228) 2008. https:\/\/doi.org\/10.3843\/GLOWM.10175","DOI":"10.3843\/GLOWM.10175"},{"key":"458_CR27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.idc.2009.06.008","volume":"23","author":"ME Levison","year":"2009","unstructured":"Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am. 2009;23:791\u20137.","journal-title":"Infect Dis Clin North Am"},{"key":"458_CR28","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/0035-9203(86)90250-6","volume":"80","author":"IF Cook","year":"1986","unstructured":"Cook IF, Cochrane JP, Edstein MD. Race-linked differences in serum concentrations of dapsone, monoacetyldapsone and pyrimethamine during malaria prophylaxis. Trans R Soc Trop Med Hyg. 1986;80:897\u2013901.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"458_CR29","first-page":"B5263","volume":"63","author":"M Julsgaard","year":"2016","unstructured":"Julsgaard M. Adherence to medical treatment in relation to pregnancy, birth outcome & breastfeeding behavior among women with Crohn\u2019s disease. Dan Med J. 2016;63:B5263.","journal-title":"Dan Med J"},{"key":"458_CR30","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/1751-2980.12539","volume":"18","author":"L Martelli","year":"2017","unstructured":"Martelli L, Lopez A, Strobel S, Danese S, Roblin X, Baumann C, Peyrin-Biroulet L. Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. J Dig Dis. 2017;18:566\u201373.","journal-title":"J Dig Dis"},{"key":"458_CR31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40268-015-0110-z","volume":"15","author":"CO Odongo","year":"2015","unstructured":"Odongo CO, Kuteesa RB, Muhammad N, Gordon O, Francis WO, Josaphat B, et al. Trimester-specific population pharmacokinetics and other correlates of variability in sulphadoxine-pyrimethamine disposition among Ugandan pregnant women. Drugs R D. 2015;15:351\u201362.","journal-title":"Drugs R D"},{"key":"458_CR32","doi-asserted-by":"publisher","first-page":"e02291","DOI":"10.1128\/AAC.02291-16","volume":"61","author":"S Salman","year":"2017","unstructured":"Salman S, Baiwog F, Page-Sharp M, Griffin S, Karunajeewa HA, Mueller I, et al. Optimal antimalarial dose regimens for sulfadoxine-pyrimethamine with or without azithromycin in pregnancy based on population pharmacokinetic modeling. Antimicrob Agents Chemother. 2017;61:e02291-2316.","journal-title":"Antimicrob Agents Chemother"},{"key":"458_CR33","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/psp4.12181","volume":"6","author":"M De Kock","year":"2017","unstructured":"De Kock M, Tarning J, Workman L, Nyunt MM, Adam I, Barnes KI, et al. Pharmacokinetics of sulfadoxine and pyrimethamine for intermittent preventive treatment of malaria during pregnancy and after delivery. CPT Pharmacomet Syst Pharmacol. 2017;6:430\u20138.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"458_CR34","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1093\/ajhp\/54.23.2714","volume":"54","author":"MC Nahata","year":"1997","unstructured":"Nahata MC, Morosco RS, Hipple TF. Stability of pyrimethamine in a liquid dosage formulation stored for three months. Am J Health Syst Pharm. 1997;54:2714\u20136.","journal-title":"Am J Health Syst Pharm"},{"key":"458_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000014254","volume":"78","author":"G Peytavin","year":"2000","unstructured":"Peytavin G, Leng JJ, Forestier F, Saux M, Hohlfeld P, Farinotti R. Placental transfer of pyrimethamine studied in an ex vivo placental perfusion model. Biol Neonate. 2000;78:83\u20135.","journal-title":"Biol Neonate"},{"key":"458_CR36","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1128\/AAC.40.6.1360","volume":"40","author":"JM Jacobson","year":"1996","unstructured":"Jacobson JM, Davidian M, Rainey PM, Hafner R, Raasch RH, Luft BJ. Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. Antimicrob Agents Chemother. 1996;40:1360\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"458_CR37","first-page":"435","volume":"116","author":"U Pleyer","year":"2019","unstructured":"Pleyer U, Gross U, Schl\u00fcter D, Wilking H, Seeber F. Toxoplasmosis in Germany. Dtsch Arztebl Int. 2019;116:435\u201344.","journal-title":"Dtsch Arztebl Int"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-020-00458-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40001-020-00458-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-020-00458-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T13:27:30Z","timestamp":1606138050000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-020-00458-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1186\/s40001-020-00458-7","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"22 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Plasma drug concentration analyses in pregnant women in our series had been requested by their treating gynaecologists\/obstetricians. The corresponding results were extracted from the existing clinical records of PT patients and transferred to a coded data base for evaluation. Because of the retrospective observational nature of the study and the lack of any modification in the management of patients, the need for informed consent was waived. The remnants of serum samples of patients with OT had been stored after routine analyses for drug tolerability after approval of the biobank by the institutional ethics committee, Kantonale Ethik-Kommission Bern, registration number 152\/08. All but one patient were above 18\u00a0years of age at the time of sampling and had signed informed general consent approving the use of their coded data and biomaterials collected during their therapy at our institution.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"JGG acts as advisor for several pharmaceutical companies and contributes to several clinical studies. The underlying manuscript is independent of these activities. None of the authors received direct or indirect support for this study or have any conflicting interests with the data that are presented herein. None of the other authors report any potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}